Rescue of Immunotherapy-Refractory Metastatic Merkel Cell Carcinoma With Conventionally Fractionated Radiotherapy and Concurrent Pembrolizumab

Merkel cell carcinoma has historically had dismal prognosis with limited cytotoxic chemotherapy options that provide durable control of metastatic disease. The advent of anti-programmed death protein (anti-PD1)/anti-programmed death-ligand 1 (anti-PD-L1) directed immunotherapy has shown initial prom...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Front Oncol
Glavni autori: Bloom, Brooke C., Augustyn, Alexander, Pezzi, Todd A., Menon, Hari, Mayo, Lauren L., Shah, Shalin J., Schwartz, David L., Chmura, Steven J., Johnson, Faye M., Welsh, James W., Chun, Stephen G.
Format: Artigo
Jezik:Inglês
Izdano: Frontiers Media S.A. 2019
Teme:
Oncology
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6459944/
https://ncbi.nlm.nih.gov/pubmed/31024834
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2019.00223
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items